Medicines for Malaria Venture
Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999 to reduce malaria in disease-endemic countries using antimalarial drugs.
History
[edit]MMV was launched in 1999,[1] with funding of US$4 million from the Government of Switzerland, the Department for International Development (UK), the Government of the Netherlands, the World Bank, and the Rockefeller Foundation. A founder and an initial key employee was Dr Robert Ridley who served at the chief Scientific Officer until 2001.[1][2]
Governance
[edit]MMV is governed by a board of directors. The Chairman in 2022 was Alan Court.[3] MMV has a board of directors in North America, an Expert Scientific Advisory Committee which helps to identify projects, an Access & Product Management Advisory Committee and a Global Safety Board which reviews projects.[4]
Projects
[edit]MMV's project portfolio includes, drug-resistant strains of Plasmodium falciparum, safety for small children (less than 6 months old) and in pregnancy. It also includes Plasmodium vivax, severe malaria and transmission-blocking treatment.[citation needed] MMV publishes a pipeline showing the drugs and developments it is involved with.[5]
Open Source Malaria
[edit]MMV started the Open Source Malaria project,[6] which encourages people to share procedures and results of open source research.[7] The Open Source Malaria, with researchers at the University of Sydney, supervised high school students at Sydney Grammar School who adapted a synthesis of Daraprim (pyrimethamine) using a less hazardous method in 2016.[8][9]
References
[edit]- 1 2 "Applying science to the diseases of poverty". Bulletin of the World Health Organization. 85: 509–510. July 2007. ISSN 0042-9686.
- ↑ "Robert Ridley". Flame Tree Initiative. 5 August 2024. Retrieved 22 April 2026.
- ↑ "Board of Directors | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 1 May 2024. Retrieved 12 December 2022.
- ↑ "People & governance | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 1 May 2024. Retrieved 12 December 2022.
- ↑ "MMV's pipeline of antimalarial drugs". Medicines for Malaria Venture. Retrieved 22 April 2026.
- ↑ "OpenSourceMalaria". OpenWetWare. 14 May 2017.
- ↑ "OpenSourceMalaria:FAQ". OpenWetWare.
- ↑ University of Sydney (30 November 2016). "Breaking good: School students make costly drug cheaply using open source approach". Eurekalert.
- ↑ Knopf, Ehsan (1 December 2016). "Sydney high school students spend $27 to recreate drug that has retailed for $148k". 9news.com.au.
External links
[edit]- Official website
- Medicine for Malaria Venture's Project Portfolio
- Roll Back Malaria Progress and Impact Series
| International | |
|---|---|
| National | |
